• PDF: Delivered by email usually within 48 UK business hours.

PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022

  • Publication Date:July 2013
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:112
  • ISBN:1658537

PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Being the most populated nation in the world and having a government with ample resources, China could potentially observe astounding AD drug growth during the forecast period. Unfortunately, we do not envision this to occur within the next 10 years due to China's acceptance of its underdeveloped healthcare infrastructure. The lack of access to healthcare in rural parts of the nation, the limited provision of social services, and limited efforts to maintain adequate public health suggest that there are many areas that require significant changes before the topic of AD can be properly addressed.

Scope

- Overview of Alzheimer's Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Alzheimer's Disease market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer's Disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China
Table of Contents

1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 17
3.2 Symptoms 29
4 Disease Management 31
4.1 Diagnosis 31
4.1.1 Probable Alzheimer's Disease Dementia 32
4.1.2 Possible AD Dementia 33
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 33
4.1.4 Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process 34
4.1.5 Preclinical AD 34
4.1.6 Mild Cognitive Impairment 35
4.2 Treatment Overview 37
4.3 China 40
4.3.1 Diagnosis 40
4.3.2 Clinical Practice 40
5 Competitive Assessment 42
5.1 Overview 42
5.2 Strategic Competitor Assessment 42
5.3 Product Profiles - Major Brands 45
5.3.1 Aricept (donepezil hydrochloride) 45
5.3.2 Exelon (rivastigmine, rivastigmine tartrate) 49
5.3.3 Razadyne (galantamine hydrobromide) 54
5.3.4 Namenda (memantine hydrochloride) 58
6 Opportunity and Unmet Need 62
6.1 Unmet Needs Overview 62
6.1.1 Public Awareness 64
6.1.2 Specialized Institutions at Local Levels 65
6.1.3 Screening and Diagnosis 65
6.1.4 Early Intervention 66
6.1.5 Improved Clinical Trial Design 67
6.1.6 Effective Therapy 68
6.1.7 Behavioral Treatments 69
6.2 Gap Analysis 69
6.2.1 Disease Prevention 70
6.2.2 Diagnosis from Biomarkers 71
6.2.3 Behavioral Therapies 72
7 Pipeline Assessment 73
7.1 Overview 73
7.2 Early-Stage Pipeline Assessment 73
7.3 AD Pipeline by Mechanism of Action 75
7.4 Enzymatic Processing 76
7.5 Immunization 77
7.6 Anti-Aggregation 77
7.7 “Me-Too” 78
7.8 Novel Therapeutic Approaches 79
7.9 Technology Trends Analytic Framework 79
7.10 Promising Drugs in Clinical Development 80
8 Market Outlook 82
8.1 China 82
8.1.1 Forecast 82
8.1.2 Key Events 85
8.1.3 Drivers and Barriers 85
9 Appendix 87
9.1 Bibliography 87
9.2 Abbreviations 98
9.3 Methodology 104
9.4 Forecasting Methodology 104
9.4.1 Diagnosed AD patients 104
9.4.2 Percent Drug-treated Patients 105
9.4.3 Drugs Included in Each Therapeutic Class 105
9.4.4 General Pricing Assumptions 106
9.4.5 Individual Drug Assumptions 106
9.4.6 Generic Erosion 108
9.5 Physicians and Specialists Included in this Study 108
9.6 About the Authors 109
9.6.1 Author 109
9.6.2 Global Head of Healthcare 110
9.7 About GlobalData 111
9.8 Disclaimer 111



List of Tables

Table 1:Symptoms of AD 30
Table 2:Guidelines for the Treatment of AD 37
Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012 38
Table 4:Leading Branded Treatments for AD, 2013 43
Table 5:Product Profile - Aricept 46
Table 6:Aricept SWOT Analysis, 2013 49
Table 7:Product Profile- Exelon 50
Table 8:Exelon SWOT Analysis, 2012 53
Table 9:Product Profile - Razadyne 55
Table 10:Razadyne SWOT Analysis, 2013 57
Table 11:Product Profile- Namenda 59
Table 12:Namenda SWOT Analysis, 2013 61
Table 13:Overall Unmet Needs - Current Level of Attainment 63
Table 14:Clinical Unmet Needs - Gap Analysis, 2013 70
Table 15:Technology Trends Analytic Framework for the AD Pipeline, 2012 80
Table 16:Comparison of Therapeutic Classes in Development for AD, 2013 80
Table 17:Comparison of Therapeutic Classes in Development for AD, 2013 81
Table 18:Sales Forecasts ($m) for AD in China, 2012-2022 83
Table 19:Key Events Impacting Sales for AD in China, 2012-2022 85
Table 20:AD Market in China - Drivers and Barriers in China, 2012-2022 85



List of Figures

Figure 1:Atrophy of the Brain in AD 19
Figure 2:Key Pathological Features in AD Versus a Healthy Neuron 21
Figure 3:Non-Amyloidogenic Metabolism of APP 23
Figure 4:Amyloidogenic Metabolism of APP 24
Figure 5:Neurofibrillary Tangles 26
Figure 6:Oxidative Damage Due to Free Radicals 28
Figure 7:Strategic Competitor Assessment of the Marketed Products in AD, 2013 44
Figure 8:AD - Pipeline Drugs by Target, 2012 74
Figure 9:Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022 81
Figure 10:Sales for AD in China by Drug Class, 2012-2022 84
+44 20 8816 8548

Ask a question about PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022

Enter the characters you see in the picture below
Captcha